DZ Bank’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $70.6M | Sell |
1,163,953
-917,126
| -44% | -$53.5M | 0.06% | 160 |
|
|
2025
Q4 | $112M | Sell |
2,081,079
-201,454
| -9% | -$9.69M | 0.1% | 133 |
|
|
2025
Q3 | $103M | Sell |
2,282,533
-3,523,960
| -61% | -$165M | 0.09% | 135 |
|
|
2025
Q2 | $269M | Sell |
5,806,493
-11,266,654
| -66% | -$553M | 0.27% | 81 |
|
|
2025
Q1 | $1.04B | Buy |
17,073,147
+4,603,041
| +37% | +$268M | 1.17% | 19 |
|
|
2024
Q4 | $705M | Buy |
12,470,106
+10,913,708
| +701% | +$610M | 0.72% | 38 |
|
|
2024
Q3 | $80.5M | Sell |
1,556,398
-162,409
| -9% | -$7.62M | 0.08% | 145 |
|
|
2024
Q2 | $71.4M | Sell |
1,718,807
-9,648
| -0.6% | -$432K | 0.07% | 145 |
|
|
2024
Q1 | $93.7M | Buy |
1,728,455
+25,069
| +1% | +$1.28M | 0.1% | 130 |
|
|
2023
Q4 | $87.4M | Buy |
1,703,386
+44,643
| +3% | +$2.34M | 0.11% | 125 |
|
|
2023
Q3 | $96.3M | Buy |
1,658,743
+100,824
| +6% | +$6.18M | 0.14% | 104 |
|
|
2023
Q2 | $99.6M | Buy |
1,557,919
+104,394
| +7% | +$7M | 0.15% | 101 |
|
|
2023
Q1 | $101M | Sell |
1,453,525
-28,895
| -2% | -$2.04M | 0.17% | 98 |
|
|
2022
Q4 | $107M | Buy |
1,482,420
+41,126
| +3% | +$3.1M | 0.19% | 96 |
|
|
2022
Q3 | $102M | Sell |
1,441,294
-53,768
| -4% | -$3.9M | 0.19% | 82 |
|
|
2022
Q2 | $115M | Buy |
1,495,062
+526,020
| +54% | +$40.1M | 0.21% | 78 |
|
|
2022
Q1 | $70.8M | Buy |
969,042
+296,754
| +44% | +$19.9M | 0.11% | 124 |
|
|
2021
Q4 | $42M | Sell |
672,288
-2,677,942
| -80% | -$157M | 0.06% | 187 |
|
|
2021
Q3 | $198M | Sell |
3,350,230
-3,084,150
| -48% | -$203M | 0.32% | 62 |
|
|
2021
Q2 | $430M | Sell |
6,434,380
-1,997,243
| -24% | -$130M | 0.7% | 45 |
|
|
2021
Q1 | $532M | Buy |
8,431,623
+821,437
| +11% | +$51.1M | 0.98% | 25 |
|
|
2020
Q4 | $471M | Sell |
7,610,186
-475,939
| -6% | -$29.3M | 1% | 24 |
|
|
2020
Q3 | $487M | Buy |
8,086,125
+658,889
| +9% | +$39.7M | 1.17% | 18 |
|
|
2020
Q2 | $437M | Buy |
7,427,236
+5,376,660
| +262% | +$322M | 1.2% | 21 |
|
|
2020
Q1 | $114M | Buy |
2,050,576
+480,437
| +31% | +$29.4M | 0.39% | 70 |
|
|
2019
Q4 | $100M | Sell |
1,570,139
-370,998
| -19% | -$21.2M | 0.26% | 83 |
|
|
2019
Q3 | $98.4M | Buy |
1,941,137
+10,168
| +0.5% | +$478K | 0.29% | 80 |
|
|
2019
Q2 | $87.6M | Buy |
1,930,969
+294,800
| +18% | +$13.7M | 0.27% | 85 |
|
|
2019
Q1 | $78.1M | Buy |
1,636,169
+669,263
| +69% | +$33.3M | 0.25% | 90 |
|
|
2018
Q4 | $49.3M | Buy |
+966,906
| New | +$52M | 0.19% | 108 |
|
|
2018
Q3 | – | Sell |
-346,578
| Closed | -$19.2M | – | 776 |
|
|
2018
Q2 | $19.2M | Buy |
346,578
+93,570
| +37% | +$5.05M | 0.07% | 201 |
|
|
2018
Q1 | $13.6M | Buy |
253,008
+162,991
| +181% | +$10.5M | 0.05% | 249 |
|
|
2017
Q4 | $5.52M | Buy |
90,017
+32,145
| +56% | +$2.01M | 0.02% | 360 |
|
|
2017
Q3 | $3.69M | Buy |
57,872
+6,535
| +13% | +$382K | 0.02% | 421 |
|
|
2017
Q2 | $2.86M | Buy |
51,337
+30,852
| +151% | +$1.68M | 0.01% | 434 |
|
|
2017
Q1 | $1.11M | Buy |
20,485
+4,000
| +24% | +$219K | 0.01% | 551 |
|
|
2016
Q4 | $964K | Buy |
+16,485
| New | +$901K | ﹤0.01% | 545 |
|
Other funds holding BMY
VCM
VPM
DZ Bank's BMY Position: Q1 2026 in Review
DZ Bank reduced its Bristol-Myers Squibb (BMY) stake by 44% in Q1 2026, selling an estimated $53.5M and leaving 1,163,953 shares worth $70.6M. The position accounts for 0.06% of the portfolio, ranked #160.
DZ Bank first reported a position in BMY in Q4 2016 and has held it in 37 quarters since. The position peaked at $1.04B in Q1 2025. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- DZ Bank held 1,163,953 shares of Bristol-Myers Squibb worth $70.6M as of Q1 2026.
- DZ Bank sold 917,126 Bristol-Myers Squibb shares in Q1 2026, an estimated $53.5M.
- Bristol-Myers Squibb made up 0.06% of DZ Bank's portfolio in Q1 2026, its #160 holding.
- DZ Bank first reported a position in Bristol-Myers Squibb in Q4 2016 and has held it in 37 quarters since.
- DZ Bank's Bristol-Myers Squibb position peaked at $1.04B in Q1 2025.
- 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on DZ Bank's 13F filing for Q1 2026, filed 15 May 2026.